How Semax and Selank differ on structure, origin, classification and evidence tier, and where a direct comparison breaks down.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro (about 813.9 Da). It corresponds to the ACTH(4-10) fragment of adrenocorticotropic hormone with a Pro-Gly-Pro extension at the C-terminus. The extension is a design feature intended to slow breakdown. Our Semax research overview covers its evidence in more detail.
Selank is also a synthetic heptapeptide, with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (about 751.9 Da). It is built on tuftsin, the tetrapeptide Thr-Lys-Pro-Arg, and carries the same Pro-Gly-Pro extension.
| Semax | Selank | |
|---|---|---|
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Thr-Lys-Pro-Arg-Pro-Gly-Pro |
| Parent sequence | ACTH(4-10) | Tuftsin |
| Parent molecule | Pituitary hormone fragment | Immunoglobulin-derived tetrapeptide |
| Shared feature | Pro-Gly-Pro extension | Pro-Gly-Pro extension |
| Origin | Russian research institutes | Russian research institutes |
| Supplied format | Lyophilised vial | Lyophilised vial |
| Current catalogue batch | 100239 (HPLC 99.533%) | 100243 (HPLC 99.620%) |
Both were developed in Russia and are described in the Russian literature as pharmaceutical products. Neither is a licensed medicine in the United Kingdom, and the materials supplied here are laboratory reagents.
Mass is a practical identifier here. The two differ by roughly 62 Da, so a certificate reporting a mass far from the expected value is describing a different material rather than a variation of the one listed.
The two are paired in retail listings, but the pairing is conventional. They share a C-terminal Pro-Gly-Pro extension and a country of origin. They do not share a parent molecule, and no common documented target makes one a version of the other.
Evidence is also not comparable. Each compound's published record comes from a small number of research groups, mostly in rodent and cell models, and we are not aware of a head-to-head study. Findings for one cannot be used to rank the other, and no table in this article can supply a ranking the literature does not contain.
A large share of the primary literature for both appears in Russian journals, many of them in English translation. Study designs, animal strains and reporting conventions differ from study to study, which makes cross-study comparison harder still.
A comparison is legitimate on questions that have documentary answers: sequence, parent molecule, mass, supplied format and what each batch certificate reports. It is not legitimate on questions that need head-to-head data, such as relative performance, tolerability or suitability for a given purpose. Where a page ranks the two on those, it is presenting a preference as a finding.
Each certificate reports identity and measured purity for the batch tested, and nothing about biological effect. Published reports are in the COA library; the product records are Semax 10mg and Selank 10mg, and both sit in the nootropic category.
The guides to reading a peptide COA and understanding HPLC purity explain what those documents can and cannot show. Buying guides are available for Semax and Selank.
Materials sold on this site are supplied solely for non-clinical in-vitro laboratory research. They must not be ingested, injected, inhaled, applied or otherwise administered to a human or animal.
We do not provide dosing, routes of administration, treatment guidance, cosmetic-use guidance or in-vivo protocols. Preparation, storage and handling must follow a validated institutional SOP, the material documentation and an appropriate risk assessment.
What retatrutide is, how it is classified, where its development stands, and what published research does and does not establish.
Research DocumentationWhich adverse events were reported in published retatrutide trials, how often, and what those trials can and cannot tell you.
Site materials are supplied solely for non-clinical in-vitro laboratory research. They must not be used in or on humans or animals. We do not provide dosing, routes of administration, treatment, cosmetic-use or in-vivo guidance. Read the legal and research-use terms.